BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tornai T, Vitalis Z, Sipeki N, Dinya T, Tornai D, Antal-Szalmas P, Karanyi Z, Tornai I, Papp M. Macrophage activation marker, soluble CD163 is an independent predictor of short-term mortality in patients with cirrhosis and bacterial infection. Liver Int. 2016; Epub ahead of print. [PMID: 27031405 DOI: 10.1111/liv.13133] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Feng S, Zhu L, Wang D, Li C, Chen Y, Chen X, Liu J, Huang W, Ling Y, Huang W. Rigidity-Tuned Full-Color Emission: Uncommon Luminescence Change from Polymer Free-Volume Variations. Adv Mater 2022;:e2201337. [PMID: 35417926 DOI: 10.1002/adma.202201337] [Reference Citation Analysis]
2 Raszeja-Wyszomirska J, Niewiński G, Graczyńska A, Morawiec S, Janik MK, Kornasiewicz O. Clinical Implication of Plasma CD163 in Patients With Acute-on-Chronic Liver Failure. Transplant Proc 2022:S0041-1345(22)00192-0. [PMID: 35523597 DOI: 10.1016/j.transproceed.2022.02.048] [Reference Citation Analysis]
3 Janka T, Tornai T, Borbély B, Tornai D, Altorjay I, Papp M, Vitális Z. Deleterious effect of proton pump inhibitors on the disease course of cirrhosis. Eur J Gastroenterol Hepatol 2020;32:257-64. [PMID: 31464790 DOI: 10.1097/MEG.0000000000001499] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
4 Zhang Z, Ma K, Yang Z, Cheng Q, Hu X, Liu M, Liu Y, Liu T, Zhang M, Luo X, Chen T, Ning Q. Development and Validation of a Clinical Predictive Model for Bacterial Infection in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. Infect Dis Ther 2021;10:1347-61. [PMID: 33991329 DOI: 10.1007/s40121-021-00454-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Tornai D, Vitalis Z, Jonas A, Janka T, Foldi I, Tornai T, Sipeki N, Csillag A, Balogh B, Sumegi A, Foldesi R, Papp M, Antal-Szalmas P. Increased sTREM-1 levels identify cirrhotic patients with bacterial infection and predict their 90-day mortality. Clin Res Hepatol Gastroenterol 2021;45:101579. [PMID: 33773436 DOI: 10.1016/j.clinre.2020.11.009] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Khanam A, Kottilil S. Abnormal Innate Immunity in Acute-on-Chronic Liver Failure: Immunotargets for Therapeutics. Front Immunol 2020;11:2013. [PMID: 33117329 DOI: 10.3389/fimmu.2020.02013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
7 Irvine KM, Ratnasekera I, Powell EE, Hume DA. Causes and Consequences of Innate Immune Dysfunction in Cirrhosis. Front Immunol 2019;10:293. [PMID: 30873165 DOI: 10.3389/fimmu.2019.00293] [Cited by in Crossref: 39] [Cited by in F6Publishing: 56] [Article Influence: 13.0] [Reference Citation Analysis]
8 Thomsen KL, Robertson FP, Holland-Fischer P, Davidson BR, Mookerjee RP, Møller HJ, Jalan R, Grønbæk H. The Macrophage Activation Marker Soluble CD163 is Associated With Early Allograft Dysfunction After Liver Transplantation. J Clin Exp Hepatol 2019;9:302-11. [PMID: 31360022 DOI: 10.1016/j.jceh.2018.09.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
9 Palyu E, Harsfalvi J, Tornai T, Papp M, Udvardy M, Szekeres-Csiki K, Pataki L, Vanhoorelbeke K, Feys HB, Deckmyn H, Tornai I. Major Changes of von Willebrand Factor Multimer Distribution in Cirrhotic Patients with Stable Disease or Acute Decompensation. Thromb Haemost 2018;118:1397-408. [PMID: 29972862 DOI: 10.1055/s-0038-1661393] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
10 Solé C, Pose E, Solà E. Editorial: macrophage activation markers predict prognosis and decompensation in patients with cirrhosis-linking gut permeability, inflammation and cirrhosis progression. Aliment Pharmacol Ther 2018;47:851-3. [PMID: 29446139 DOI: 10.1111/apt.14523] [Reference Citation Analysis]
11 Dinya T, Tornai T, Vitalis Z, Tornai I, Balogh B, Tornai D, Antal-Szalmas P, Sumegi A, Andrikovics H, Bors A, Tordai A, Papp M. Functional polymorphisms of innate immunity receptors are not risk factors for the non-SBP type bacterial infections in cirrhosis. Liver Int 2018;38:1242-52. [PMID: 29235260 DOI: 10.1111/liv.13664] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
12 Marazzi MG, Randelli F, Brioschi M, Drago L, Romanò CL, Banfi G, Massaccesi L, Crapanzano C, Morelli F, Corsi Romanelli MM, Galliera E. Presepsin: A potential biomarker of PJI? A comparative analysis with known and new infection biomarkers. Int J Immunopathol Pharmacol 2018;31:394632017749356. [PMID: 29251000 DOI: 10.1177/0394632017749356] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
13 Foldi I, Tornai T, Tornai D, Sipeki N, Vitalis Z, Tornai I, Dinya T, Antal-Szalmas P, Papp M. Lectin-complement pathway molecules are decreased in patients with cirrhosis and constitute the risk of bacterial infections. Liver Int 2017;37:1023-31. [PMID: 28109038 DOI: 10.1111/liv.13368] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
14 Papp M, Tornai T, Vitalis Z, Tornai I, Tornai D, Dinya T, Sumegi A, Antal-Szalmas P. Presepsin teardown - pitfalls of biomarkers in the diagnosis and prognosis of bacterial infection in cirrhosis. World J Gastroenterol 2016; 22(41): 9172-9185 [PMID: 27895404 DOI: 10.3748/wjg.v22.i41.9172] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]